10
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4671 |
BN82002
CDC25 Phosphatase Inhibitor I |
Phosphatase | Metabolism |
BN82002 (CDC25 Phosphatase Inhibitor I) 是一种CDC25 phosphatase 家族的有效的、不可逆的、选择性的泛抑制剂。它显示出比 CD45 酪氨酸磷酸酶高约 20 倍的选择性。 | |||
T16357 |
DA-3003-1
NSC 663284 |
Phosphatase | Metabolism |
DA-3003-1 (DA-3003-1) 是一种可渗透进细胞膜且具有有效性和选择性的 Cdc25 dual specificity phosphatase 抑制剂,具有抗肿瘤活性,对 Cdc25B2、Cdc25A、Cdc25B2 和 Cdc25C具有抑制作用。 | |||
T7078 |
NSC 95397
|
Apoptosis; Phosphatase | Apoptosis; Metabolism |
NSC 95397 是一种选择性的Cdc25双特异性磷酸酶抑制剂。它抑制丝裂原活化蛋白激酶磷酸酶-1(MKP-1),通过 MKP-1 和 ERK1/2 途径抑制结肠癌细胞的增殖并诱导细胞凋亡。 | |||
T11929 |
M2N12
|
Phosphatase | Metabolism |
M2N12 是一种高度选择性的细胞分裂周期蛋白磷酸酶 25C 抑制剂,IC50值为 0.09 μM。它还抑制 Cdc25A 和 Cdc25B 的活性,IC50值分别为 0.53 μM 和 1.39 μM。它具有抗肿瘤活性,可研究癌症。 | |||
T12263L |
NSC305787 hydrochloride
(Rac)-NSC305787 hydrochloride |
Others | Others |
NSC305787 hydrochloride ((Rac)-NSC305787 hydrochloride) 是一种可透过细胞膜且具有选择性和有效性的小分子 Cdc25 dual specificity phosphatase 和 EZR 双重抑制剂,在胰腺癌细胞中显示出抗肿瘤活性,对Cdc25B2, Cdc25A,Cdc25B2 和 Cdc25C 具有抑制作用。NSC 663284 抑制 NSD2 (IC50 of 170 nM) 酶的活性。 | |||
T69091 |
CBP501
|
||
CBP501 is a peptide with G2 checkpoint-abrogating activity. G2 checkpoint inhibitor CBP501 inhibits multiple serine/threonine kinases, including MAPKAP-K2, C-Tak1, and CHK1, that phosphorylate serine 216 of the dual-specific phosphatase Cdc25C (cell division checkpoint 25 C); disruption of Cdc25C activity results in the inhibition of Cdc25C dephosphorylation of the mitotic cyclin-dependent kinase complex Cdc2/cyclin B, preventing entry into the mitotic phase of the cell cycle. | |||
T38447 |
BN82002 hydrochloride
|
||
BN82002 hydrochloride is a potent, selective, and irreversible inhibitor of the CDC25 phosphatase family. It inhibits CDC25A, CDC25B2, CDC25B3, CDC25C, and 25C-cat with IC50 values of 2.4, 3.9, 6.3, 5.4, and 4.6 μM, respectively. Additionally, BN82002 hydrochloride exhibits approximately 20-fold greater selectivity over CD45 tyrosine phosphatase. | |||
T73526 |
M5N36
|
||
M5N36 是一种有效的选择性Cdc25C 抑制剂,对 Cdc25A、Cdc25B、Cdc25C 的IC50值分别为 0.15、0.19、0.06 µM。M5N36 显示出抗增殖活性并增加 p-CDK1 和 p-CDK2 的表达。 | |||
T16848 |
SB-218078
|
Chk; PKC | Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling |
SB-218078 is less potently inhibits Cdc2 (IC50: 250 nM) and PKC (IC50: 1000 nM). SB-218078 is a potent, ATP-competitive, and cell-permeable checkpoint kinase 1 inhibitor that inhibits Chk1 phosphorylation of cdc25C (IC50: 15 nM). | |||
T71217 |
MPT0B214
|
||
MPT0B214 is a novel and potent microtubule inhibitor with potential anticancer activity. MPT0B214 inhibited tubulin polymerization through strongly binding to the tubulin's colchicine-binding site and had cytotoxic activity in a variety of human tumor cell lines. After treatment with MPT0B214, KB cells were arrested in the G2-M phase before cell death occurred, which were associated with upregulation of cyclin B1, dephosphorylation of Cdc2, phosphorylation of Cdc25C and elevated expression of th... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TN5639 |
Rocaglaol
Ferrugin,Aglaiastatin A |
||
Rocaglaol is a potent anticancer drug that induces apoptosis of LNCaP cells through the mitochondrial pathway and its G2/M-phase cell cycle arrest is associated with the down-regulation of Cdc25C and the dephosphorylation of Cdc2. Rocaglaol can reduce tis |